Pricing Log in Create free account

Fractyl Health, Inc. (GUTS) vs TScan Therapeutics, Inc. (TCRX)

Fractyl Health, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Fractyl Health, Inc. and TScan Therapeutics, Inc. are of similar size ($12.3M and $11.9M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −22.5%. Fractyl Health, Inc. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 17 metrics below, Fractyl Health, Inc. leads on 9 and TScan Therapeutics, Inc. on 8.

Valuation

Metric GUTS TCRX Biotechnology median
P/E n/m n/m 10.60
P/S 133.58 3.29 9.40
P/B n/m 0.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.05 0.37 0.66
EV/Sales (45.93) (6.19) 9.02
Earnings yield (1,123.85%) (505.56%) (32.88%)
Free cash flow yield (668.02%) (506.23%) (23.13%)

Profitability

Metric GUTS TCRX Biotechnology median
Gross margin 46.24% 100.00% 68.51%
Operating margin 0.00% (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity 1,063.04% (95.80%) (51.96%)
Return on assets (146.75%) (50.09%) (46.06%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric GUTS TCRX Biotechnology median
Revenue growth (TTM) (22.50%) 2.15% 6.76%
EPS growth (last fiscal year) (14.81%) 12.28% 29.88%
Revenue growth, 5-year CAGR — 56.92% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric GUTS TCRX Biotechnology median
Debt to equity (18.29) 0.47 0.00
Current ratio 3.15 3.37 4.97
Net debt to EBITDA 0.53 0.90 1.01

Dividend

Metric GUTS TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GUTS TCRX Biotechnology median
Market cap 11.88m 12.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack